Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
51 pending office actions • 21 art units • 44 examiners • 0 of 51 (0%) have an AI response strategy ready • 34 patents granted in the last 365 days
Janssen Biotech Inc. currently has 51 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 51 actions are assigned to 44 distinct examiners, which indicates that the majority of the pending matters are being reviewed by different individuals. The portfolio is also active across 21 distinct art units, suggesting that the company's Biotechnology & Pharmaceuticals applications span a wide range of specialized technical classifications within the patent office.
The busiest examiner for this portfolio is Duffy, Bradley, who is currently managing 2 of the pending office actions. This concentration of 2 actions with one examiner is very low, as the remaining workload is distributed among the other 44 distinct examiners. For practitioners, this decentralized environment means that the outcomes of the 51 pending office actions will be determined by a wide range of individual examiner perspectives rather than a single point of contact.
The involvement of 21 distinct art units requires a prosecution strategy that accounts for the different procedural standards within the Biotechnology & Pharmaceuticals groups. While Duffy, Bradley handles 2 of the pending office actions, the overall portfolio's success depends on navigating the requirements of the 44 distinct examiners involved. Practitioners must be prepared to address the specific technical nuances of each of the 21 distinct art units to ensure a cohesive approach across the 51 pending actions.
Based on the USPTO statutory response window for each pending office action. 18 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 18 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (2%) |
| §101 + other | 5 (10%) |
| §103 only | 11 (22%) |
| §102 only | 1 (2%) |
| §112 only | 3 (6%) |
| Double-patenting only | 5 (10%) |
| Double-patenting + other | 13 (25%) |
| Multi-statute (no §101) | 12 (24%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DUFFY, BRADLEY | 2 | 54.5% | +45.8% |
| ALSOMAIRY, SARAH ABDOALATIF | 2 | 57.8% | +30.2% |
| POPA, ILEANA | 2 | 21.4% | +15.1% |
| HOLTZMAN, KATHERINE ANN | 2 | 65.7% | +58.3% |
| HUYNH, PHUONG N | 2 | 65.7% | +53.6% |
| SULLIVAN, DENNIS JOHN | 2 | 57.3% | +49.1% |
| GUSTILO, ESTELLA M | 2 | 53.6% | +34.5% |
| SANG, HONG | 1 | 55.0% | +62.4% |
| IVICH, FERNANDO NMN | 1 | 48.7% | +69.8% |
| ROSENTHAL, ANDREW S | 1 | 51.8% | +38.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17235974 | NEUROLOGIC TOXICITY ASSESSMENT METHODS AND SYSTEMS FOR DOCUMENTING CHANGES IN HANDWRITING | ROBERTS, ANNA L | 164d overdue |
| 17825244 | ANTI-IDIOTYPIC ANTIBODIES AGAINST ANTI-CD79B ANTIBODIES | GUSTILO, ESTELLA M | 147d overdue |
| 18052172 | METHODS OF TREATING CANCERS AND ENHANCING EFFICACY OF GPRC5DXCD3 BISPECIFIC ANTIBODIES | GUSTILO, ESTELLA M | 88d overdue |
| 18166878 | Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody | FORD, VANESSA L | 17d overdue |
| 18143749 | Use of Anti-EGFR/Anti-Met Antibody to Treat Liver Cancer | MOSELEY II, NELSON B | 6d |
| 17918140 | SYSTEMS, MATERIALS, AND METHODS FOR REVERSED-PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (RP-HPLC) IDENTIFICATION OF MULTI-SPECIFIC MOLECULES | BERKELEY, EMILY R | 20d |
| 17182429 | CAPACITY OPTIMIZATION ACROSS DISTRIBUTED MANUFACTURING SYSTEMS | LEE, PO HAN | 34d |
| 19418900 | METHODS OF TREATING HIGH RISK MULTIPLE MYELOMA | SANG, HONG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17825244 | ANTI-IDIOTYPIC ANTIBODIES AGAINST ANTI-CD79B ANTIBODIES | GUSTILO, ESTELLA M | 147d overdue |
| 18052172 | METHODS OF TREATING CANCERS AND ENHANCING EFFICACY OF GPRC5DXCD3 BISPECIFIC ANTIBODIES | GUSTILO, ESTELLA M | 88d overdue |
| 17240609 | Materials and Methods for Treating Juvenile Idiopathic Arthritis | HOLTZMAN, KATHERINE ANN | 13d |
| 17691050 | Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses | ALSOMAIRY, SARAH ABDOALATIF | 27d |
| 18216026 | Use of Anti-EGFR/Anti-Met Antibody to Treat Gastric or Esophageal Cancer | SULLIVAN, DENNIS JOHN | 54d |
| 19637933 | Subcutaneous Formulations Of Anti-CD38 Antibodies And Their Uses | DUFFY, BRADLEY | — |
| 19637868 | Subcutaneous Formulations Of Anti-CD38 Antibodies And Their Uses | DUFFY, BRADLEY | — |
| 19418900 | METHODS OF TREATING HIGH RISK MULTIPLE MYELOMA | SANG, HONG | — |
| Art Unit | Apps |
|---|---|
| 1646 | 7 |
| 1643 | 4 |
| 1642 | 3 |
| 1674 | 3 |
| 1600 | 3 |
| 1634 | 2 |
| 1641 | 2 |
| 3783 | 2 |
| 1678 | 1 |
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19637933 | Subcutaneous Formulations Of Anti-CD38 Antibodies And Their Uses | DUFFY, BRADLEY | 1643 | §102§103DP | Non-Final OA | — | Pending | Apr 02, 2026 |
| 19637868 | Subcutaneous Formulations Of Anti-CD38 Antibodies And Their Uses | DUFFY, BRADLEY | 1643 | §103DP | Non-Final OA | — | Pending | Apr 02, 2026 |
| 19418900 | METHODS OF TREATING HIGH RISK MULTIPLE MYELOMA | SANG, HONG | 1646 | §102§103§112 | Final Rejection | — | Pending | Dec 12, 2025 |
| 19281154 | METHODS AND COMPOSITIONS FOR MONITORING THE TREATMENT OF RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA | IVICH, FERNANDO NMN | 1678 | §101§102§103§112Other | Non-Final OA | — | Pending | Jul 25, 2025 |
| 18939761 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING AMINOPYRIMIDINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE, OR SOLVATE THEREOF | ROSENTHAL, ANDREW S | — | §103DP | Non-Final OA | — | Pending | Nov 07, 2024 |
| 18846889 | SHELL FOR SMALL VIAL TO FIT INTO INJECTOR OR CAP REMOVER | WHITROCK, ZACHARIAH KIRBY | — | §102§103§112 | Non-Final OA | — | Pending | Sep 13, 2024 |
| 18771839 | Combination Therapies with Anti-CD38 Antibodies | ALSOMAIRY, SARAH ABDOALATIF | — | §103DP | Non-Final OA | — | Pending | Jul 12, 2024 |
| 18711131 | Method of Treating Geographic Atrophy with a Gene Therapy Vector Expressing Soluble CD59 | POPA, ILEANA | — | §102§103 | Non-Final OA | — | Pending | May 17, 2024 |
| 18703264 | BIOSYNTHETIC MONOVALENT BINDING MOLECULES WITH ENHANCED EFFECTOR FUNCTIONS | HOLTZMAN, KATHERINE ANN | — | §103§112DP | Non-Final OA | — | Pending | Apr 19, 2024 |
| 18639233 | METHODS FOR TREATING MULTIPLE MYELOMA | FAUST, AMBER KATHLEEN | — | §102§103DP | Non-Final OA | — | Pending | Apr 18, 2024 |
| 18613945 | USE OF APPROVED BISPECIFIC EGFR AND MET SPECIFIC ANTIBODY DRUG PRODUCT TO TREAT NON-SMALL CELL LUNG CANCER | LANDSMAN, ROBERT S | — | §103 | Non-Final OA | — | Pending | Mar 22, 2024 |
| 18691254 | CD33 x Vd2 MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER | WEIDNER, ADAM M | — | §112DP | Non-Final OA | — | Pending | Mar 12, 2024 |
| 18592234 | BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA | MELCHIOR, JAMES RYLAND | — | §101§102§103§112DP | Non-Final OA | — | Pending | Feb 29, 2024 |
| 18588224 | COMPOSITIONS COMPRISING A BISPECIFIC GPRC5D/CD3 ANTIBODY | JOHNSON, TIRONE DEREK | — | §101§103 | Non-Final OA | — | Pending | Feb 27, 2024 |
| 18583364 | Neoantigens Expressed In Ovarian Cancer And Their Uses | POPA, ILEANA | 1633 | §103 | Non-Final OA | — | Pending | Feb 21, 2024 |
| 18439951 | METHODS FOR TREATING MULTIPLE MYELOMA | BUNNER, BRIDGET E | — | DP | Non-Final OA | — | Pending | Feb 13, 2024 |
| 18545113 | ONCOLYTIC VIRUS AND USES THEREOF | MARVICH, MARIA | 1634 | §112 | Non-Final OA | — | Pending | Dec 19, 2023 |
| 18528157 | ANTI- GPRC5D ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND GPRC5D AND CD3, AND USES THEREOF | NATARAJAN, MEERA | — | §112DP | Non-Final OA | — | Pending | Dec 04, 2023 |
| 18559029 | Device and Method for Sorting Biological Cells | MUTREJA, JYOTI NAGPAUL | 1798 | §102 | Non-Final OA | — | Pending | Nov 03, 2023 |
| 18558859 | UNIVERSAL RETARGETING OF ONCOLYTIC HSV | GRABER, JAMES J | 1631 | §103§112 | Non-Final OA | — | Pending | Nov 03, 2023 |
| 18499720 | BCMA-TARGETED CAR-T CELL THERAPY OF MULTIPLE MYELOMA | HUYNH, PHUONG N | 1641 | §102§103§112DP | Non-Final OA | — | Pending | Nov 01, 2023 |
| 18555924 | MOLECULES WITH ENGINEERED ANTIBODY CONSTANT REGION VARIANTS | HUYNH, PHUONG N | 1641 | §102§103§112 | Non-Final OA | — | Pending | Oct 18, 2023 |
| 18222093 | Dosing Regimen for Therapies Comprising Bispecific Anti-EGFR/C-Met Antibodies | DONOGHUE, BRITTNEY ERIN | 1675 | §103§112DP | Non-Final OA | — | Pending | Jul 14, 2023 |
| 18344973 | MATERIALS AND METHODS FOR BIOENGINEERED IPSC POPULATIONS | CANDELARIA, JULIANA IRENE | 1634 | §103 | Final Rejection | 21d | Pending | Jun 30, 2023 |
| 18216026 | Use of Anti-EGFR/Anti-Met Antibody to Treat Gastric or Esophageal Cancer | SULLIVAN, DENNIS JOHN | 1642 | §103Other | Non-Final OA | 54d | Pending | Jun 29, 2023 |
| 18210885 | Safe and Effective Method of Treating Ulcerative Colitis with Anti-IL12/IL23 Antibody | BRISTOL, LYNN ANNE | 1643 | §103Other | Non-Final OA | — | Pending | Jun 16, 2023 |
| 18327577 | METHOD OF TREATING INFLAMMATORY BOWEL DISEASE WITH A COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF ALPHA | SAOUD, CHRISTINE J | 1645 | DP | Final Rejection | 46d | Pending | Jun 01, 2023 |
| 18199007 | Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody | LOCKARD, JON MCCLELLAND | 1647 | §112 | Final Rejection | 6d | Pending | May 18, 2023 |
| 18143749 | Use of Anti-EGFR/Anti-Met Antibody to Treat Liver Cancer | MOSELEY II, NELSON B | 1642 | §102§103Other | Non-Final OA | 6d | Pending | May 05, 2023 |
| 18249807 | PROTEINS COMPRISING DELTA-LIKE LIGAND 3 (DLL3) ANTIGEN BINDING DOMAINS AND THEIR USES | LI, RUIXIANG | 1674 | §112 | Non-Final OA | — | Pending | Apr 20, 2023 |
| 18300288 | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib and Dexamethasone | SULLIVAN, DENNIS JOHN | 1642 | §103DP | Non-Final OA | — | Pending | Apr 13, 2023 |
| 18180693 | Palm Activated Drug Delivery Device | SCHMIDT, EMILY LOUISE | 3783 | DP | Non-Final OA | — | Pending | Mar 08, 2023 |
| 18166878 | Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody | FORD, VANESSA L | 1674 | §102§103 | Final Rejection | 17d overdue | Pending | Feb 09, 2023 |
| 18106531 | Methods for Reducing Infusion-Related Reactions in Patients Treated with EGFR/Met Bispecific Antibodies | REDDIG, PETER J | 1646 | §103DP | Final Rejection | 28d | Pending | Feb 07, 2023 |
| 18080639 | VACCINES BASED ON MUTANT CALR AND JAK2 AND THEIR USES | BARRERA, IMMACULADA | 1671 | DP | Final Rejection | 74d overdue | Pending | Dec 13, 2022 |
| 18009135 | CONTROLLED RELEASE OF SELF-EMBEDDING PARTICLES FOR LOCALIZED DRUG DELIVERY | KIM, DANIELLE A | 1613 | §103 | Non-Final OA | — | Pending | Dec 08, 2022 |
| 18053904 | STABLE FORMULATIONS COMPRISING A BISPECIFIC BCMA/CD3 ANTIBODY | DUNN, LINDSAY MICHELLE | 1600 | §102§103 | Non-Final OA | — | Pending | Nov 09, 2022 |
| 18052172 | METHODS OF TREATING CANCERS AND ENHANCING EFFICACY OF GPRC5DXCD3 BISPECIFIC ANTIBODIES | GUSTILO, ESTELLA M | 1646 | §103§112Other | Final Rejection | 88d overdue | Pending | Nov 02, 2022 |
| 17918140 | SYSTEMS, MATERIALS, AND METHODS FOR REVERSED-PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (RP-HPLC) IDENTIFICATION OF MULTI-SPECIFIC MOLECULES | BERKELEY, EMILY R | 1796 | §101§103 | Final Rejection | 20d | Pending | Oct 11, 2022 |
| 17860244 | Manufacturing Methods for Producing Anti-TNF Antibody Compositions | CUNNINGCHEN, KATHLEEN MARY | 1646 | §103§112 | Non-Final OA | — | Pending | Jul 08, 2022 |
| 17825244 | ANTI-IDIOTYPIC ANTIBODIES AGAINST ANTI-CD79B ANTIBODIES | GUSTILO, ESTELLA M | 1646 | §103§112Other | Non-Final OA | 147d overdue | Pending | May 26, 2022 |
| 17752892 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROSTATE CANCER | SKOKO III, JOHN JOSEPH | 1643 | §103§112DP | Non-Final OA | 49d overdue | Pending | May 25, 2022 |
| 17767263 | MATERIALS AND METHODS FOR MASS SPECTROMETRIC PROTEIN ANALYSIS | SIMMONS, VALERIE MICHELLE | 1758 | §103 | Non-Final OA | 9d | Pending | Apr 07, 2022 |
| 17691050 | Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses | ALSOMAIRY, SARAH ABDOALATIF | 1646 | §103 | Final Rejection | 27d | Pending | Mar 09, 2022 |
| 17630706 | MATERIALS AND METHODS FOR POLYMERIC ANTIBODY RECEPTOR TARGETING | JOHANSEN, PETER N. | 1600 | DP | Non-Final OA | — | Pending | Jan 27, 2022 |
| 17615959 | ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS | XIE, XIAOZHEN | 1674 | §103 | Non-Final OA | 20d | Pending | Dec 02, 2021 |
| 17417022 | Beta-Galactosidase Alpha Peptide as a Non-Antibiotic Selection Marker and Uses Thereof | WHITEMAN, BRIAN A | 1600 | §103 | Final Rejection | — | Pending | Jun 21, 2021 |
| 17240609 | Materials and Methods for Treating Juvenile Idiopathic Arthritis | HOLTZMAN, KATHERINE ANN | 1646 | §103Other | Non-Final OA | 13d | Pending | Apr 26, 2021 |
| 17235974 | NEUROLOGIC TOXICITY ASSESSMENT METHODS AND SYSTEMS FOR DOCUMENTING CHANGES IN HANDWRITING | ROBERTS, ANNA L | 3791 | §101§102 | Final Rejection | 164d overdue | Pending | Apr 21, 2021 |
| 17182429 | CAPACITY OPTIMIZATION ACROSS DISTRIBUTED MANUFACTURING SYSTEMS | LEE, PO HAN | 3623 | §101 | Final Rejection | 34d | Pending | Feb 23, 2021 |
| 16983212 | MULTI-UNIT DRUG DELIVERY DEVICES AND METHODS | VOKES, KATHLEEN PAIGE | 3783 | §103§112 | Non-Final OA | — | Pending | Aug 03, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial